FDMT vs. KRYS, CRSP, IBRX, IMVT, SWTX, ACLX, APGE, DNLI, IOVA, and IMCR
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Krystal Biotech (KRYS), CRISPR Therapeutics (CRSP), ImmunityBio (IBRX), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Arcellx (ACLX), Apogee Therapeutics (APGE), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), and Immunocore (IMCR). These companies are all part of the "biological products, except diagnostic" industry.
Krystal Biotech (NASDAQ:KRYS) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends.
Krystal Biotech has a net margin of 0.00% compared to Krystal Biotech's net margin of -436.30%. 4D Molecular Therapeutics' return on equity of -5.74% beat Krystal Biotech's return on equity.
86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 14.1% of Krystal Biotech shares are owned by insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Krystal Biotech had 2 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 4 mentions for Krystal Biotech and 2 mentions for 4D Molecular Therapeutics. Krystal Biotech's average media sentiment score of 1.26 beat 4D Molecular Therapeutics' score of 0.98 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.
Krystal Biotech received 244 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. Likewise, 66.83% of users gave Krystal Biotech an outperform vote while only 65.38% of users gave 4D Molecular Therapeutics an outperform vote.
Krystal Biotech presently has a consensus target price of $177.63, suggesting a potential upside of 10.98%. 4D Molecular Therapeutics has a consensus target price of $44.22, suggesting a potential upside of 84.49%. Given Krystal Biotech's higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Krystal Biotech.
Krystal Biotech has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Krystal Biotech has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.94, indicating that its stock price is 194% more volatile than the S&P 500.
Summary
Krystal Biotech beats 4D Molecular Therapeutics on 12 of the 17 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
